SecBot SecBot
SECBOTREPLAY Home › Report › TCRT

TCRT · Alaunos Therapeutics reported an integrated preclinical readout for…

Alaunos Therapeutics, Inc. · 8-K filed May 26, 2026 at 11:00 ET

At the news

BEARISHIMPACT 6/10

8-K filed May 26, 2026 at 11:00 ET

Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral non-hormonal obesity candidate, showing multi-axis metabolic improvements in diet-induced obese mouse studies. However, the company disclosed it had only ~$0.354 million cash as of March 31, 2026, with runway extending only into Q2 2026, making the financing risk acute and the preclinical data largely academic without capital to advance the program.

  • ALN1003 showed body weight reductions up to -30.5% (p<0.0001) in high-dose DIO mouse study, but with dose aversion and dehydration confounders
  • Cash and cash equivalents were approximately $0.354 million as of March 31, 2026
  • Cash runway extends only into the second quarter of 2026
  • Company intends to pursue additional financing to support continued operations

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access